This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a single-centred, non-randomised trial. The duration of follow-up was not explicitly stated, nor was any loss to follow-up reported.
Analysis of effectiveness
The analysis of effectiveness appears to have been conducted on an intention to treat basis, although the authors did not explicitly state this. The threshold targets were reported to be 0.5 x 10^9/L neutrophils and 50 x 10^9/L platelets. The primary health outcomes used in the analysis were: the median period to reach >0.5 x 10^9/L neutrophils; the median period to reach >50 x 10^9/L platelets; the median number of febrile days; and the median days when parenteral antibiotics were given in each group.
The authors did not draw any comparisons between the characteristics of the groups at baseline. They also did not make any adjustments for confounding factors.
Effectiveness results
No patients died from the complications of ABSCT, and all patients reached the threshold of >0.5 x 10^9/L neutrophils.
The median period to reach >0.5 x 10^9/L neutrophils was 11 days (range: 9 -29) in group A and 11 days (range: 8 -15) in group B, and significantly shorter (9 days, range: 8 -17) in group C, (p<0.01).
The median period to reach 50 x 10^9/L platelets was 18 days (range: 11 -229) in group A and 17 days (range: 13 -76) in group B, and significantly shorter (14 days, range: 10 -24) in group C, (p<0.05).
In 6 patients in group A the platelet count did not reach 50 x 10^9/L, although it did reach 20 x 10^9/L. All other patients reached the desired threshold.
The median days when parenteral antibiotics were given were 7 (range: 0 -30) in group A, 10.5 (range: 4 -30) in group B, and 8.5(range: 0 -23) in group C. There was no significant difference between any two of the three groups.
Eleven patients (47.8%) received RC-MAP (packed red blood concentrate) in group A, as did 11 patients (44%) in group B and 7 patients (33.3%) in group C. There was no significant difference between any two of the three groups.
All patients received packed platelet concentrate (PC) transfusions after ABSCT. The median units of transfused PC were 40 in groups A and B, and 25 in group C. The patients in group C received significantly fewer PC transfusions than patients in groups A and B, (p<0.05).
Overall, 19 patients (27.5%) had no febrile episodes and 30 patients 43.5%) had 1 to 3 days of fever (temperature >/=
